Langford N J, Martin U, Ruprah M, Ferner R E
West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham, UK.
J Clin Pharm Ther. 2002 Dec;27(6):465-7. doi: 10.1046/j.1365-2710.2002.00438.x.
The pharmacokinetics of venlafaxine in therapeutic doses is well established. It is metabolized by the cytochrome P450 enzymes including CYP2D6. The toxicokinetics in overdose is less well known.
A 33-year-old Caucasian female who ingested 3.0 g venlafaxine, and 210 mg zolpidem. The patient remained symptomatic for the following 24 h. Plasma pharmacokinetic analysis demonstrated a prolonged elimination half-life of venlafaxine, estimated to be 15.3 h. We postulate that the patient was a slow metabolizer of substrates for CYP2D6, an enzyme known to exhibit polymorphism.
文拉法辛治疗剂量的药代动力学已明确。它由细胞色素P450酶包括CYP2D6代谢。过量服用时的毒代动力学则鲜为人知。
一名33岁的白种女性，摄入了3.0克文拉法辛和210毫克唑吡坦。患者在接下来的24小时内仍有症状。血浆药代动力学分析显示文拉法辛的消除半衰期延长，估计为15.3小时。我们推测该患者是CYP2D6底物的慢代谢者，CYP2D6是一种已知存在多态性的酶。
